Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $1.8 million.

  • Ligand Pharmaceuticals' Capital Expenditures was N/A to $15,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.7 million, marking a year-over-year change of. This contributed to the annual value of $1.8 million for FY2024, which is 48.28% down from last year.
  • As of FY2024, Ligand Pharmaceuticals' Capital Expenditures stood at $1.8 million, which was down 48.28% from $3.5 million recorded in FY2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Capital Expenditures peaked at $17.9 million during FY2022, and registered a low of $1.8 million during FY2024.
  • In the last 3 years, Ligand Pharmaceuticals' Capital Expenditures had a median value of $3.5 million in 2023 and averaged $7.8 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 104.58% in 2022, then slumped by 80.35% in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Capital Expenditures (Yearly) stood at $4.5 million in 2020, then soared by 96.52% to $8.8 million in 2021, then surged by 104.58% to $17.9 million in 2022, then tumbled by 80.35% to $3.5 million in 2023, then crashed by 48.28% to $1.8 million in 2024.